89bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company focusing on innovative therapies for liver and cardio-metabolic diseases, has announced its participation in several investor conferences this June.

• SVB Leerink CybeRx Series: Liver Disease Day - One-on-one meetings on June 17, 2021.
• Raymond James Human Health Innovation Conference - Panel discussion on NASH on June 23, 2021, at 12:00 PM ET.
• Piper Sandler EASL Takeaway Day - One-on-one meetings on June 28, 2021.

The company’s leading product candidate is BIO89-100, targeting NASH and severe hypertriglyceridemia.

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in the following upcoming investor conferences in June:

• SVB Leerink CybeRx Series: Liver Disease Day
  Format: One-on-one investor meetings
  Date: Thursday, June 17, 2021

• Raymond James Human Health Innovation Conference
  Panel Discussion: “State” of the Union: Current Thinking in NASH
  Date: Wednesday, June 23, 2021 at 12:00 PM ET

• Piper Sandler EASL Takeaway Day
  Format: One-on-one investor meetings
  Date: Monday, June 28, 2021

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

What conferences will 89bio participate in during June 2021?

89bio will attend the SVB Leerink CybeRx Series on June 17, the Raymond James Human Health Innovation Conference on June 23, and the Piper Sandler EASL Takeaway Day on June 28.

What is the date of the Raymond James Human Health Innovation Conference panel discussion?

The panel discussion at the Raymond James Human Health Innovation Conference will take place on June 23, 2021, at 12:00 PM ET.

What is BIO89-100 developed by 89bio?

BIO89-100 is a glycoPEGylated analog of FGF21, developed for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

What is the focus of 89bio, Inc.?

89bio focuses on developing innovative therapies for liver and cardio-metabolic diseases.

Where is 89bio headquartered?

89bio is headquartered in San Francisco, with operations in Herzliya, Israel.